Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack. Scientific Publication

Sep 15, 2019 | Magazine: Clinical Cancer Research

Salas-Benito D (1,2), Melero I (2,3,4), Ponz-Sarvise M (5,4,6).

No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.

CITATION Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17

see publication in pubmed

Our authors

Imagen del Dr. Ignacio Melero Bermejo, especialista en Inmunología de la Clínica Universidad de Navarra.

Dr. Ignacio Melero Bermejo Curriculum

Researcher | Principal Investigator Combination Strategies for Translational Immunotherapy Research Group

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.

Dr. Mariano Ponz-Sarvisé Curriculum

Researcher | Principal Investigator Solid Tumor Research Program